Bill Haney, Dragonfly
November 20, 2019 07:13 AM ESTUpdated November 21, 09:26 AM
R&D

Ab­b­Vie lines up a new pre­clin­i­cal R&D al­liance with the deal­mak­ers at nat­ur­al killer play­er Drag­on­fly

John Carroll

Editor & Founder

Bill Haney is build­ing on his rep as one of the most pro­lif­ic deal­mak­ers in pre­clin­i­cal R&D, adding a new al­liance for Drag­on­fly Ther­a­peu­tics with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times